The Australian pharmaceutical market presents significant opportunities for Indian exporters, particularly in the generic drug segment. With a market valued at approximately USD 6.4 billion in 2024, the demand for cost-effective medications is substantial. The government's initiatives to promote generics, including favorable reimbursement policies and mandatory substitution practices, have significantly increased their penetration.
Indian pharmaceutical companies have already established a strong presence in Australia, with total exports valued at USD 821.8 million over the past five years. The top five Indian exporters—Strides Pharma Science Limited, Ipca Laboratories Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, and Alembic Pharmaceuticals Limited—have collectively contributed significantly to this figure. Their success underscores the potential for further growth and expansion in the Australian market.
Given the Australian government's support for generics and the increasing demand for cost-effective medications, Indian exporters are well-positioned to expand their market share. Focusing on high-demand therapeutic areas such as oncology, cardiovascular diseases, and diabetes can further enhance growth prospects. Additionally, aligning with the Pharmaceutical Benefits Scheme (PBS) can facilitate market entry and acceptance, as the PBS subsidizes a wide range of prescription medications, ensuring affordability and accessibility for all Australians. (amsa.org.au)
